Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluoxetine ODT in childhood and adolescent autistic disorder
NCT00515320Phase 3Completed
- Sponsor
- Neuropharm
- Start
- Aug 2007
- Primary completion
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of fluoxetine in Autism Spectrum Disorder (ASD), sponsored by Neuropharm. Started Aug 2007; status: completed.
02
Drugs
fluoxetine
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT00515320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00515320.